{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080188","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.195235+00:00","generated_at":"2026-06-13T09:26:34.475024+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Verastem Oncology CEO Stuglik retires; President Paterson appointed CEO effective Aug 1","bullets":["CEO Brian Stuglik retires effective July 31, 2023; receives $421,850 cash bonus.","President Dan Paterson appointed President and CEO effective August 1, 2023; also joins Board.","Paterson has 30+ years experience, led acquisition of avutometinib; company moving toward FDA approval in LGSOC.","Stuglik remains on Board and chairs new Commercialization Committee.","Committee members Kapur and Tollefson; annual retainers $10k, chair $20k."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080188","json":"https://secwatch.observer/filing/0001104659-23-080188.json","markdown":"https://secwatch.observer/filing/0001104659-23-080188.md","text":"https://secwatch.observer/filing/0001104659-23-080188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/0001104659-23-080188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/tm2321108d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:26:34.475024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47ab21c9a8","claim":"Brian Stuglik retired as Chief Executive Officer at Verastem, Inc..","evidence_excerpt":"On July 7, 2023, Brian Stuglik notified Verastem, Inc. (the “Company)” of his decision to retire as Chief Executive Officer of the Company, effective July 31, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/0001104659-23-080188-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"639fd59bd0","claim":"Daniel Paterson was appointed as President and Chief Executive Officer at Verastem, Inc..","evidence_excerpt":"Daniel Paterson, 62, the Company’s President and Chief Operating Officer, will be appointed to the position of President and Chief Executive Officer as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/0001104659-23-080188-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"bab0d4ab3c","claim":"Daniel Paterson was appointed as Class III director at Verastem, Inc..","evidence_excerpt":"In connection with his appointment, Mr. Paterson will also be appointed to the Board, to serve as a Class III director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465923080188/0001104659-23-080188-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}